Emerging Therapies in Persistent Human Papillomavirus Infections | OMICS International | Abstract
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Emerging Therapies in Persistent Human Papillomavirus Infections

*Corresponding Author:

Copyright: © 0  . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

To read the full article Peer-reviewed Article PDF image


Pharmaceutical companies have developed effective vaccines to prevent certain HPV infections and their associated diseases. However, these vaccine products are not for clearing the persistent HPV infections or curing pre-existing conditions. The unmet needs to treat the diseases, especially cancers, caused by persistent HPV infections remain urgent. Thus, the pharmaceutical industry and multiple medical institutions have invested into developing medications of different modalities, such as viruses, stem cells, T-cells, gene therapies, DNAs, antibodies, antigens, and more. These emerging therapies are the focus of this review.


Recommended Conferences
Share This Page